Clinical Trial: How Healthy Adults Respond to the Nasal Flu Vaccine

U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07726862) titled 'How Healthy Adults Respond to the Nasal Flu Vaccine' on July 21.

Brief Summary: This study is looking at how the immune system in the nose responds after receiving the FluMist nasal flu vaccine in healthy adults. FluMist is an FDA-approved influenza vaccine that is given as a nasal spray.

Healthy volunteers aged 18 to 65 who do not have chronic medical conditions, do not smoke, and have not recently received a flu vaccine will be enrolled. Participants will have three study visits over approximately one week. At the first visit, participants will be screened, give informed consent, and receive the FluMist vaccine. Nasal swabs and a...